Early Phase 1 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and willing to sign a written consent form
• People who have been diagnosed with pancreatic cancer
• People who are currently receiving, or who have received within the last 12 weeks, cancer treatment such as surgery, radiation, chemotherapy, immunotherapy, or another targeted cancer therapy
• People aged 18 or older
• People who have moderate to severe anxiety, as measured by specific anxiety questionnaires used during screening
• People whose liver function tests show adequate results during the screening period
• People who are taking certain antidepressants for anxiety (such as SSRIs) may still be eligible, provided the dose has not changed for at least 12 weeks before joining and anxiety levels still meet the required threshold
• People of childbearing potential (both women and men with partners who could become pregnant) who agree to use an appropriate form of contraception, or abstain from sex, during the study; women who could become pregnant must also have a negative pregnancy test at screening, and must inform their treating doctor and study staff immediately if pregnancy occurs or is suspected during the trial
• People who can read and understand English
• People who are able to avoid potentially hazardous activities — such as driving or operating machinery — after each dose of study medication until the following day after a full night's sleep
• People who agree not to drink alcohol while taking the study medication

Who may not be able to join:

• People whose cancer was first diagnosed 6 weeks or less before the study start date
• People who have been assessed as meeting diagnostic criteria for schizophrenia, bipolar disorder, delirium, or psychosis using a specific psychiatric interview tool
• People who score 10 or higher on a suicidal risk assessment used during screening
• People with a known allergy or hypersensitivity to ketamine
• People with a documented history of severe heart failure (confirmed with trial site), where the condition is currently uncontrolled or unstable
• People with a current or recent serious heart rhythm problem, severe chest pain (angina), or reduced blood supply to the heart, as assessed by a study doctor
• People with poorly controlled high blood pressure — specifically, a top reading above 180 or a bottom reading above 100 on two separate occasions within the past two months — whether or not they are taking blood pressure medication
• Women who are pregnant, breastfeeding, expecting to become pregnant, or planning to start breastfeeding during the trial, or women who could become pregnant but are unwilling to use contraception
• People with an uncontrolled thyroid condition (either overactive or underactive), as assessed by a study doctor
• People who have been diagnosed with dementia
• People who have taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI) within 14 days before the study start date
• People with certain blood vessel conditions, including aneurysms (weaknesses in blood vessel walls) affecting major arteries or brain vessels, or abnormal connections between arteries and veins
• People with a history of bleeding inside the brain
• People who are unwilling or unable to follow the driving restrictions or the requirement to avoid alcohol during the treatment period

Important: Always verify eligibility with the trial site directly before applying.